| T12268 |
NTP42
|
2055599-51-2
|
99.09%
|
|
|
NTP42 is an antagonist of thromboxane A2 (TXA2) receptor(IC50 of 3.278 nM)
|
| TQ0025 |
E7046
|
1369489-71-3
|
99.09%
|
|
|
E7046 is a specific, orally bioavailable EP4 antagonist (IC50: 13.5 nM, Ki: 23.14 nM), exhibiting anti-tumor activities.
|
| T5482 |
TG4-155
|
1164462-05-8
|
99.14%
|
|
|
TG4-155 is a brain penetrant EP2 antagonist (KB = 2.4 nM) that is over 1000-fold less effective at EP4 (KB = 11.4 µM) and a panel of other receptors and channels...
|
| TQ0203 |
Tafluprost
|
209860-87-7
|
99.16%
|
|
|
Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.
|
| T3520 |
Setipiprant
|
866460-33-5
|
99.16%
|
|
|
Setipiprant (ACT-129968) is an orally available, selective CRTH2 antagonist (IC50: 6.0 nM). CRTH2 is a G protein-coupled receptor for prostaglandin (PGD2). PGD2 ...
|
| T5386 |
Asapiprant
|
932372-01-5
|
99.23%
|
|
|
Asapiprant (S-555739) is a potent and selective DP1 receptor antagonist (Ki: 0.44 nM). It exhibited high affinity and selectivity for the DP1 receptor.
|
| T3174 |
Taprenepag
|
752187-80-7
|
99.32%
|
|
|
Taprenepag (CP-544326) (CP-544326) is a potent and selective prostaglandin E2 receptor agonist (EC50 = 2.8 nM). Taprenepag has been used in trials studying the t...
|
| T62525 |
TP-16
|
2332972-26-4
|
99.33%
|
|
|
TP-16 is a novel potent and selective EP4 antagonist that blocks the function of IMCs and enhances cytotoxic T cell-mediated tumor elimination in vivo.
|
| T4436 |
RO1138452
|
221529-58-4
|
99.34%
|
|
|
RO1138452 (CAY10441) is a selective and orally bioavailable antagonist of prostacyclin receptor (pKi: 8.3). It antagonizes the carbaprostacyclin-induced activati...
|
| TN1362 |
Afzelin
|
482-39-3
|
99.38%
|
|
|
Afzelin (Kaempferol-3-O-rhamnoside) has several cellular activities such as DNA-protective, antibacterial, antioxidant, and anti-inflammatory as well as UV-absor...
|
| T3889 |
Platycodin D
|
58479-68-8
|
99.43%
|
|
|
Platycodin D may stimulate TNF-α synthesis or inhibit degradation of TNF-α mRNA. Platycodin D (10/30 μM) suppresses prostaglandin E2 production in rat peritoneal...
|
| T3306 |
PF-04418948
|
1078166-57-0
|
99.45%
|
|
|
PF-04418948 is a potent EP2 receptor antagonist (IC50 = 16 nM for human EP2 receptors). Displays over 2000-fold selectivity for EP2 receptors over EP1, EP3, EP4,...
|
| T4624 |
PGD2-IN-1
|
885066-67-1
|
99.46%
|
|
|
PGD2-IN-1 (PGD2-inhibitor) is an effective DP receptor antagonist (IC50:0.3 nM), a compound that can inhibit prostaglandin D2 (PGD2) signaling. PGD2-IN-1 specifi...
|
| T2791 |
Pectolinarin
|
28978-02-1
|
99.47%
|
|
|
Pectolinarin is a Cirsium isolate with anti-inflammatory activity.
|
| T24567 |
Octimibate
|
89838-96-0
|
99.49%
|
|
|
Octimibate (Octimibato) is a non-prostaglandin platelet aggregation inhibitor and cyclic prostaglandin agonist.Octimibate is used in the treatment of cardiovascu...
|
| TQ0292 |
Grapiprant
|
415903-37-6
|
99.49%
|
|
|
Grapiprant (AAT-007) is a selective EP4 receptor antagonist. Grapiprant displaces [3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor (IC50: 35 nM, Ki: 24 n...
|
| T68155 |
Tebufelone
|
112018-00-5
|
99.52%
|
|
|
Tebufelone is a potent in vitro inhibitor of CO , a novel non-steroidal anti-inflammatory drug (NSAID) belonging to the di-tert-butylphenol (DTBP) class that has...
|
| T11211 |
EP4 receptor antagonist 1
|
2287259-07-6
|
99.53%
|
|
|
EP4 Receptor Antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist, effective for cancer immunotherapy. It inhibits both h...
|
| T1978 |
GW627368
|
439288-66-1
|
99.54%
|
|
|
GW627368 (GW 627368X)X is a novel, potent and selective antagonist of prostanoid EP4 receptor.
|
| T6399 |
AZD1981
|
802904-66-1
|
99.54%
|
|
|
AZD1981 is an effective and specific CRTh2 (DP2) receptor antagonist (IC50: 4 nM), showing >1000-fold selectivity over more than 340 other enzymes and receptors,...
|
